Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Exogenous gene expression in recombinant adenovirus for minimal impact on viral kinetics

Exogenous gene expression in recombinant adenovirus for minimal impact on viral kinetics

US Patent 11401529 · Granted Aug 2, 2022

Estimated economic value: $17,894,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Oncolytic adenovirus with enhanced replication properties comprising modificatio2025
Oncolytic adenovirus with enhanced replication properties comprising modificatio2025
Exogenous gene expression in recombinant adenovirus for minimal impact on viral 2025
Exogenous gene expression in recombinant adenovirus for minimal impact on viral 2025
Exogenous gene expression in recombinant adenovirus for minimal impact on viral 2025
Tumor-targeting synthetic adenoviruses and uses thereof2023
Tumor-targeting synthetic adenoviruses and uses thereof2023
Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound2023
Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound2023
High throughput assay for measuring adenovirus replication kinetics2021
High throughput assay for measuring adenovirus replication kinetics2021
High throughput assay for measuring adenovirus replication kinetics2021